Killer cell lectin-like receptor G1 binds three members of the classical cadherin family to inhibit NK cell cytotoxicity by Ito, Masayuki et al.
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
BRIEF DEFINITIVE REPORT
JEM © The Rockefeller University Press  $8.00
Vol. 203, No. 2,  February 20, 2006  289–295  www.jem.org/cgi/doi/10.1084/jem.20051986
289
<doi>10.1084/jem.20051986</doi><aid>20051986</aid>Killer cell lectin-like receptor G1 binds three 
members of the classical cadherin family 
to inhibit NK cell cytotoxicity
Masayuki Ito, Takuma Maruyama, Naotoshi Saito, Satoru Koganei, 
Kazuo Yamamoto, and Naoki Matsumoto
Department of Integrated Biosciences, Graduate School of Frontier Sciences, The University of Tokyo, Kashiwa, 277-8562 
Chiba, Japan
Killer cell lectin-like receptor G1 (KLRG1) is an inhibitory receptor expressed on subsets of 
natural killer (NK) cells and T cells, for which no endogenous ligands are known. Here, we 
show that KLRG1 binds three of the classical cadherins (E-, N-, and R-), which are ubiqui-
tously expressed in vertebrates and mediate cell–cell adhesion by homotypic or heterotypic 
interactions. By expression cloning using the mouse KLRG1 tetramer as a probe, we identi-
fi  ed human E-cadherin as a xenogeneic ligand. We also identifi  ed a syngeneic interaction 
between mouse KLRG1 and mouse E-cadherin. Furthermore, we show that KLRG1 binds 
N- and R-cadherins. Finally, we demonstrate that E-cadherin binding of KLRG1 prevents 
the lysis of E-cadherin–expressing targets by KLRG1+ NK cells. These results suggest that 
KLRG1 ligation by E-, N-, or R-cadherins may regulate the cytotoxicity of killer cells to 
prevent damage to tissues expressing the cadherins.
NK cells play a pivotal role in innate immunity 
by their direct cytolytic activity and production 
of regulatory cytokines (1). NK cell recogni-
tion of targets involves two types of receptors, 
activating receptors and inhibitory receptors 
(2). Integration of opposing signals from these 
two types of receptors determines the activa-
tion of NK cells. These receptors are classifi  ed 
into two structurally defi   ned groups, Ig-like 
receptors and C-type lectin-like receptors. The 
former group includes killer cell Ig-like recep-
tors (KIRs) (3, 4), whereas the latter group in-
cludes CD94/NKG2 (KLRD/KLRC), rodent 
Ly49 (KLRA), NKG2D (KLRK), NKR-P1 
(KLRB), and KLRG1. Many of the receptors, 
such as KIR, CD94/NKG2, NKG2D, and 
Ly49, have been shown to bind either MHC 
class I molecules or molecules structurally re-
lated to MHC class I (2, 4, 5). However, the 
MHC class I–specifi  c receptors do not appear 
to account for all NK cell specifi  cities, some of 
which may be conveyed by orphan receptors 
expressed on the NK cells (6).
KLRG1 is an orphan C-type lectin-like re-
ceptor that was originally identifi  ed as the mast 
cell function–associated antigen (MAFA) ex-
pressed on the rat basophilic leukemia cell line 
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RBL-2H3 (7). Antibody-mediated ligation of 
KLRG1 inhibits release of infl  ammatory medi-
ators from RBL-2H3 cells induced by cross-
linking of FcεRI. In contrast, in mouse and 
human, KLRG1 is expressed on subsets of NK 
cells and T cells (8–12). In normal mice,  30% 
of resting NK cells express KLRG1, and viral 
infections increase the percentage of KLRG1-
expressing NK cells (13). In humans,  60% of 
NK cells from healthy adult donors express 
KLRG1 (14). Although T cell expression of 
KLRG1 in normal mice is restricted to small 
subpopulations of eff   ector–memory type T 
cells (11, 12, 15), expression of KLRG1 is up-
regulated in mouse CD8+ T cells by infection 
with pathogens (12, 16). In humans, KLRG1 is 
expressed on  40% of CD8+ T cells and  20% 
of CD4+ T cells from healthy adult donors 
(14). Furthermore, over 90% of CD8+ T cells 
specifi  c to CMV or EBV express KLRG1 dur-
ing the latent stages of these chronic infections 
(17). Consistent with the inhibitory activity in 
RBL-2H3 cells (7), KLRG1 has an immune 
receptor tyrosine-based inhibitory motif (ITIM) 
in its cytoplasmic domain, and mAb-mediated 
cross-linking of KLRG1 inhibits NK cell func-
tion (13). Although rat KLRG1 has been shown 
to bind saccharides (7), endogenous ligands for 
KLRG1 have not been identifi  ed.
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To identify endogenous KLRG1 ligands, we generated a 
KLRG1 tetramer and a KLRG1 reporter cell line, which al-
lowed us to identify cell lines   expressing KLRG1 ligands. By 
expression cloning using the KLRG1 tetramer as a probe, we 
identify human E-cadherin as a xenogeneic ligand. We also 
show that mouse KLRG1 binds three members of the mouse 
classical   cadherin family and KLRG1 binding by its ligand 
inhibits NK cell cytotoxicity.
RESULTS AND D  I  S  C  U  S  S  I  O  N 
Expression of putative KLRG1 ligands on mouse 
and human cell lines
To identify endogenous ligands for KLRG1, we generated a 
fl  uorescently labeled tetramer of the entire extracellular do-
main of mouse KLRG1. The KLRG1 tetramer was tested for 
binding to a panel of mouse and human cell lines. Of the 
mouse cell lines, the KLRG1 tetramer bound a myoblast cell 
line, two melanoma lines, and three carcinoma cell lines (Fig. 
1 A). The binding was inhibited when the KLRG1 tetramer 
was preincubated with an excess of the anti–mouse KLRG1 
mAb 2F1 (unpublished data). The mouse KLRG1 tetramer 
also bound human melanoma and carcinoma cell lines (Fig. 
1 B), suggesting that the KLRG1 ligands are highly conserved 
across species. These results were confi   rmed using the 
KLRG1 reporter cell line BWZ.muKLRG1, which enabled 
us to visualize binding of the mouse KLRG1 ectodomain to 
a putative ligand by converting the signal into β-galactosidase 
expression. All of the mouse cell lines that bound the KLRG1 
tetramer induced the expression of β-galactosidase in the 
mouse KLRG1 reporter cells, whereas cell lines that did not 
bind the KLRG1 tetramer did not stimulate the KLRG1 re-
porter cells (Fig. 1 C). Similar results were obtained for the 
human cell lines (Fig. 1 D). These results suggest that putative 
KLRG1 ligands are expressed ubiquitously in melanoma and 
carcinoma cell lines.
Biochemical characterization of putative KLRG1 ligands
We next characterized the biochemical nature of the putative 
KLRG1 ligand. The binding of the KLRG1 tetramer to the 
mouse and human cell lines was sensitive to pretreatment 
of the cells with trypsin-EDTA (Fig. S1, available at http://
www.jem.org/cgi/content/full/jem.20051986/DC1), sug-
gesting that the putative KLRG1 ligand on these cells is a 
membrane protein. We also precipitated the putative KLRG1 
ligand expressed on the human lung carcinoma line EBC-1, 
which was stained most intensely with the mouse KLRG1 
tetramer among the cell lines tested. Mouse KLRG1 specifi  -
cally precipitated a protein with an apparent mass on SDS-
PAGE of 115 kD under nonreducing conditions and 120 kD 
under reducing conditions (Fig. 2 A). These results suggest 
Figure 1.  Expression of a putative KLRG1 ligand on mouse and 
human cell lines. (A and B) A panel of mouse (A) and human (B) cell 
lines were stained with mouse KLRG1 tetramer (fi  lled histograms) 
or PE-streptavidin alone (solid lines) and analyzed by FACS. LLC, 
Lewis lung cancer. (C and D) The mouse KLRG1 reporter cell line 
BWZ.muKLRG1(black bars) or the control line BWZ.EGFP (white bars) 
were cocultured with the indicated mouse (C) or human (D) cell lines 
and then assayed for β-galactosidase activity. Representative data 
(means ± SD of triplicate samples) from one of three independent 
experiments are shown.JEM VOL. 203, February 20, 2006  291
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that the putative KLRG1 ligand expressed on EBC-1 cells is 
a protein with an apparent mass of 120 kD and has a single 
or a small number of intramolecular disulfi  de bond(s).
Binding of KLRG1 to E-cadherin
To identify the ligand expressed on EBC-1, we constructed 
a cDNA library from EBC-1 and transduced mouse BW5147 
thymoma cells, which do not bind the KLRG1 tetramer. 
The cells were stained with the mouse KLRG1 tetramer to 
enrich the KLRG1 tetramer-positive population by FACS. 
After three rounds of enrichment, we obtained a population 
that was uniformly stained with the KLRG1 tetramer (Fig. 
2 B), and this population also stimulated the mouse KLRG1 
reporter cells (Fig. 2 C). PCR recovery of the integrated 
cDNA gave an  5-kb DNA fragment, which encoded hu-
man E-cadherin, a Ca2+-dependent adhesion molecule that 
plays pivotal roles in tissue morphogenesis and in the forma-
tion of cellular junctions (18, 19). Consistent with these data, 
a mAb to human E-cadherin stained the KLRG1 tetramer-
positive population (Fig. 2 D). The biochemical nature of 
E-cadherin, such as sensitivity to trypsin-EDTA treatment, 
the apparent migration on SDS-PAGE, and the presence of 
a single intramolecular disulfi  de bond, is also consistent with 
that of the putative KLRG1 ligand expressed on EBC-1 cells. 
To confi  rm a syngeneic interaction between KLRG1 and 
E-cadherin, mouse E-cadherin was expressed on BW5147 
cells (Fig. 3 A). BW5147 cells expressing mouse E-cadherin 
bound the mouse KLRG1 tetramer and stimulated the mouse 
KLRG1 reporter cells (Fig. 3, A and B). In the complemen-
tary experiment, a dodecameric form of a mouse E-cad-
herin–Fc fusion protein was used to stain BW5147 cells 
transduced with mouse KLRG1 using a bicistronic expres-
sion vector carrying cDNA for expression of an EGFP 
marker. The E-cadherin–Fc fusion protein stained the EGFP+ 
KLRG1+ cells, and the staining was blocked by a mAb against 
KLRG1 (Fig. 3, C and D). Conversely, the E-cadherin–Fc 
fusion protein did not stain the EGFP-negative population of 
KLRG1 transductants or control transductants. Collectively, 
these results indicate that KLRG1 binds E-cadherin.
Binding of KLRG1 to three members of classical cadherins
Because the KLRG1 tetramer stained melanoma cells, which do 
not usually express E-cadherin (20), we examined E-  cadherin 
expression in the mouse cell lines that bound the KLRG1 tet-
ramer. We found that two melanomas, B16 and clone M-3, 
the Colon-26 carcinoma, and the C2C12 myoblast cell line 
expressed little or no E-cadherin (Fig. 4 A). By RT-PCR 
analysis, we found that these cell lines express other mem-
bers of the classical cadherin family, such as N- or M-cadherin 
(Fig. S2, available at http://www.jem.org/cgi/content/full/
jem.20051986/DC1). These observations led us to test whether 
KLRG1 binds other cadherins. We independently transduced 
BW5147 cells with each of the fi  ve mammalian classical cad-
herins (E-, N-, P-, R-, or M-) or one of the type II cadherins 
(VE-) using the bicistronic expression vector, which also ex-
presses the EGFP marker, and tested those cells for KLRG1 
tetramer binding. The expression of cadherins was confi  rmed 
by fl  ow cytometry or Western blotting (Fig. S3, available at
 http://www.jem.org/cgi/content/full/jem.20051986/DC1). 
The KLRG1 tetramer stained cells transduced with E-, N-, 
or R-cadherins, but not those transduced with P-, M-, or 
VE-cadherins (Fig. 4 B). These re  sults were confi  rmed by the 
KLRG1 reporter assays (Fig. 4 C). In RT-PCR analysis, all the 
mouse cell lines that bound the KLRG1 tetramer expressed at 
least one of the E-, N-, or R-cadherins (Fig. S2). These data 
indicate that KLRG1 recognizes three members (E-, N-, and 
R-) of the classical cadherin family.
Classical cadherins primarily mediate cell–cell adhesion 
by homotypic interactions (18, 19). E-cadherin also partici-
pates in adhesion of intestinal intraepithelial lymphocytes to 
epithelial cells by heterotypic interactions with the αEβ7 
  integrin (21). Thus, classical cadherins function both as  ligands 
and as receptors in mediating cell–cell adhesion. Our results 
reveal a novel function of the cadherins as ligands for an 
  inhibitory receptor expressed on immune cells.
Figure 2.  Expression cloning of a KLRG1 ligand expressed on 
EBC-1 cells. (A) Biochemical characterization of the putative KLRG1 
ligand. The human EBC-1 cell line was surface labeled with 125I, and cell 
lysates were precipitated with streptavidin-beads loaded with (+) or 
without (−) biotinylated mouse KLRG1. The precipitates were separated 
by electrophoresis on an SDS-PAGE gel under reducing (R) or nonreduc-
ing (NR) conditions, and 125I-labeled proteins were visualized by phospho-
rimaging. Arrowheads indicate the bands for the putative KLRG1 ligand. 
(B) BW5147 cells were transduced with a retroviral cDNA library prepared 
from EBC-1 cells, and the KLRG1 tetramer+ population was enriched. The 
enriched KLRG1 tetramer+ population (right) or untransduced control 
BW5147 cells were stained with the mouse KLRG1 tetramer (fi  lled histo-
grams) or PE-streptavidin alone (solid lines). (C) The KLRG1 tetramer+ 
population and the control BW5147 cells were tested for stimulation of 
the KLRG1 reporter cells. Representative data (mean ± SD of triplicate 
samples) from one of three independent experiments are shown. (D) The 
KLRG1 tetramer+ population (right) or control BW5147 cells (left) were 
stained with an anti–human E-cadherin mAb and PE-anti–mouse IgG 
(fi  lled histograms) or PE-anti–mouse IgG alone (solid lines).292  IDENTIFICATION OF KLRG1 LIGANDS | Ito et al.
Binding of KLRG1 by E-cadherin inhibits NK cell cytotoxicity
Because KLRG1 has an ITIM consensus sequence in its cy-
toplasmic region and mAb-mediated cross-linking of KLRG1 
inhibits NK cell functions (13), we investigated the func-
tional consequence of the KLRG1 receptor binding to its 
  ligand. We expressed KLRG1 in the mouse NK cell line 
NK03 (Fig. 5 A), which does not normally express KLRG1, 
and examined its capacity to kill F9 cells, which express E-, 
N-, and R-cadherins. The KLRG1-expressing NK cells 
killed F9 cells less effi   ciently than the uninfected control NK 
cells, and the anti–mouse KLRG1 mAb restored the cytotox-
icity of the KLRG1 expressing NK cells to levels similar to 
Figure 3.  Binding of mouse KLRG1 to mouse E-cadherin. 
(A) BW5147 cells transduced with mouse E-cadherin (right) and control 
BW5147 cells (left) were analyzed for E-cadherin expression and binding of 
the KLRG1 tetramer. For E-cadherin expression (top), the cells were stained 
with mAb to mouse E-cadherin (ECCD-2) and a secondary antibody (fi  lled 
histograms) or the secondary antibody alone (solid lines). For binding of the 
mouse KLRG1 tetramer (bottom), the cells were stained with the KLRG1 
tetramer (fi  lled histograms) or PE-streptavidin alone (solid lines). 
(B) BW5147 cells transduced with mouse E-cadherin and control BW5147 
cells were tested for stimulation of the KLRG1 reporter cells. Representative 
data (mean ± SD of triplicate samples) from one of three independent experi-
ments are shown. (C) BW5147 cells transduced with the KLRG1-IRES-EGFP 
vector (right) or the control EGFP vector (left) were stained with the anti-
KLRG1 antibody and PE-anti–mouse IgG. (D) BW5147 cells transduced with 
the KLRG1-IRES-EGFP vector (bottom) or the control EGFP vector (top) were 
stained with E-cadherin–Fc fusion protein and PE-anti–human IgG Fc. Where 
indicated, the cells were treated with the anti-KLRG1 mAb or an isotype-
matched control mAb, before staining with the E-cadherin–Fc fusion protein.JEM VOL. 203, February 20, 2006  293
BRIEF DEFINITIVE REPORT
that of the control NK cells (Fig. 5 B). We also tested killing 
of the E-cadherin–expressing BW5147 cells by the same ef-
fectors. The KLRG1-expressing NK cells again showed a re-
duced capacity to kill E-cadherin–expressing targets, and the 
reduction was abolished by addition of an anti-KLRG1 mAb 
(Fig. 5 C). These results indicate that E-cadherin binding to 
KLRG1 on NK cells inhibits NK cell cytotoxicity.
As E-, N-, and R-cadherins are ubiquitously expressed 
among solid tissues, these tissues may be protected from at-
tack by killer cells expressing KLRG1. In this context, it is of 
note that the activation history of individual NK and T cells 
appears to regulate KLRG1 expression on the cells. NK cell 
expression of KLRG1 is up-regulated by viral infection in 
animals (13) and, in contrast, is down-regulated in MHC 
class I–defi  cient animals (22), in which NK cells are hypore-
sponsive (23). Expression of KLRG1 on CD8+ T cells, 
Figure 4.  Binding of KLRG1 to three members of the classical 
cadherin family. (A) E-cadherin expression on mouse cell lines that 
bound the KLRG1 tetramer. The indicated cell lines were stained with 
a mAb to mouse E-cadherin (ECCD-2) and FITC-anti–mouse IgG (fi  lled 
histograms) or FITC-anti–mouse IgG alone (solid lines). (B and C) BW5147 
cells were retrovirally transduced with vectors for bicistronic expression 
of EGFP and the mouse cadherins indicated. The cells were stained with 
the KLRG1 tetramer (B) or tested for stimulation of the mouse KLRG1 
reporter cells (C). In C, representative data (mean ± SD of triplicate 
  samples) from one of three independent experiments are shown.
Figure 5.  Ligation of KLRG1 on NK cells by E-cadherin inhibits 
NK cell cytotoxicity. (A) Expression of KLRG1 on the mouse NK cell line 
NK03 (left) or the cell line transduced (right) with KLRG1. The cells were 
stained with the mAb to KLRG1 and a secondary antibody (fi  lled histo-
grams) or the secondary antibody alone (solid lines). (B) Cytotoxicity of 
the control (left) or KLRG1 transduced (right) mouse NK cell line NK03 
against mouse F9 cells was assessed in a 4-h 51Cr-release assay. The as-
says were conducted in the absence (○) or the presence (●) of the anti-
KLRG1 mAb, or in the presence of an isotype-matched control mAb (△). 
(C) Cytotoxicity of the control (left) or KLRG1 transduced (right) mouse 
NK cells against E-cadherin expressing (bottom) or control (top) BW5147 
targets, both of which lack Fcγ receptors. The assays were conducted 
in the absence (○) or the presence (●) of the anti-KLRG1 mAb, or in 
the presence of an isotype-matched control mAb (△). Representative 
data (mean ± SD of triplicate samples) from one of three independent 
experiments are shown.294  IDENTIFICATION OF KLRG1 LIGANDS | Ito et al.
  especially those showing specifi  city to viral antigens, is also 
induced by viral infection (8, 12, 16, 17). Moreover, KLRG1 
is expressed on eff  ector–memory CD8+ T cells (15), which 
have experienced antigen stimulation and immediately re-
spond to antigenic stimuli. A higher threshold of activation 
for these “immune experienced” NK and T cells expressing 
KLRG1 would be imposed when their targets express E-, 
N-, or R-cadherins. This would prevent excessive damage to 
vital tissues expressing the cadherins and would also contrib-
ute to terminating the immune response.
Normally, classical cadherins are localized at tight junctions 
in epithelia and similar structures in endothelia, both of which 
form the physical barriers. Migration of leukocytes through 
these barriers is regulated by chemokines, whose action is mod-
ulated by the inhibitory receptor Ly49A in NK cells (24). In 
this context, KLRG1 may regulate transendothelial migration 
of NK and T cells that express KLRG1. Similar localization at 
the tight junctions has been observed for the poliovirus recep-
tor (CD166). CD166 recognition by DNAM-1, an activating 
receptor expressed on NK cells, as well as other leukocytes, is 
involved in the transendothelial migration of monocytes (25). 
Further studies using KLRG1-defi   cient animals or in vivo 
blocking of KLRG1 function   using mAbs against KLRG1 will 
provide insight into the physiological function of KLRG1.
The malignancy of epithelial tumors is often associated 
with down-regulation of E-cadherin, which makes tumor 
cells invasive and metastatic (26, 27). Because our results pre-
dict that tumor cells lacking E-cadherin expression would be 
more prone to killing by KLRG1+ NK cells, it is tempting to 
hypothesize that NK cells expressing KLRG1 are instrumen-
tal in surveillance of malignant tumors. This idea is analogous 
to the advocated role of inhibitory MHC class I receptors in 
surveillance of tumor cells that have lost or down-regulated 
MHC class I expression in the “missing self hypothesis” (28). 
Although KLRG1 expression on NK cells is inducible by 
  viral infections (13), there is also a compartment of NK cells 
that constitutively express KLRG1, which dominates  30% 
of mouse resting NK cells and  50% of human peripheral 
blood NK cells (8, 9, 14, 22, 29). The KLRG1+ subsets of 
resting NK cells may be involved in surveillance of malignant 
tumors that have lost their “identity” by losing or down-
  regulating the expression of E-, N-, or R-cadherins, although 
this hypothesis needs validation by in vivo studies.
Finally, our results uncover a novel role of the classical 
cadherins, which are ubiquitously expressed among solid tis-
sues and have a fundamental role in maintaining morphology 
of the solid tissues in vertebrates, in which these proteins are 
used to regulate the cytotoxicity of cells of the innate and 
  acquired immune systems.
MATERIALS AND METHODS
Cell lines, reagents, and antibodies. The BWZ.36 cell line was provided 
by N. Shastri (University of California Berkeley, Berkeley, CA). The retro-
virus vectors, pMXs and pMXs-IRES-GFP, and the retrovirus packaging 
cell line Plat-E were provided by T. Kitamura (The University of Tokyo) 
and were used for retroviral transduction throughout this study.
Culture supernatant from hybridoma cells obtained from M. Takeichi 
(Institute of Physical and Chemical Research CDB, Hyogo, Japan) was 
used to provide the rat anti–E-cadherin (ECCD-2) mAb. The other mAbs 
used were a mouse monoclonal anti–human E-cadherin (67A4; Santa 
Cruz Biotechnology, Inc.) and a hamster monoclonal anti–mouse KLRG1 
(2F1; eBioscience).
For fl  ow cytometry, PE-anti–mouse IgG F(ab′)2 or FITC-anti–mouse 
IgG F(ab′)2 fragments were used as the secondary reagents. Data were 
  acquired with a FACSCalibur system and were analyzed with CellQuest 
software (BD Biosciences).
Preparation of biotinylated KLRG1 protein and its tetramer. 
A cDNA encoding the ectodomain of mouse KLRG1 amplifi  ed by RT-PCR 
from C57BL/6J spleen cells was cloned into pET3Nbio (30). Expression, re-
folding, biotinylation, and tetramerization of the KLRG1 ectodomain were 
performed as described previously (30). The tetramer was used at 2.5–5 μg/ml 
for staining.
KLRG1 reporter assays. The construct for the KLRG1 chimeric receptor, 
muKLRG1rep-pMXs-IG, included the extracellular and transmembrane 
  regions of the mouse KLRG1 and the cytoplasmic region of the mouse 
CD3ζ chain. The muKLRG1rep-pMXs-IG vector and the empty pMXs-
IRES-GFP vector were used for transduction of the BWZ.36 cell line to 
  establish the reporter BWZ.muKLRG1 and the control BWZ.EGFP, re-
spectively. The cell lines were cultured with the indicated target cells for 
16 h, and β-galactosidase activity was determined by colorimetric assay using 
chlorophenol red-β-d-galactopyranoside (Wako) as a substrate.
Precipitation and detection of a putative KLRG1 ligand. KLRG1 
ligands were precipitated from lysates of EBC-1 cells that had been surface 
labeled with 125I using streptavidin-agarose beads loaded with the biotinyl-
ated mouse KLRG1 protein. The precipitates were analyzed on a 10% 
SDS-PAGE gel, and the gel was subjected to phosphorimaging with a 
BAS-2500 system (Fuji Photo Film).
Expression cloning. A cDNA library containing 1.4 × 106 independent 
clones was constructed using the pMXs vector and used for transduction of 
BW5147 cells. The cells positive for the KLRG1 tetramer were enriched by 
three rounds of sorting with a FACSVantage SE. Genomic DNA extracted 
from the enriched population was used for the recovery of the cDNA inserts 
by PCR amplifi   cation with primers specifi   c for the pMXs vector. The 
  amplifi   ed cDNA fragments were cloned into the pBluescript II SK(+) 
vector (Stratagene) and sequenced.
Transduction with cadherins or KLRG1. cDNAs for mouse E- and N-
cadherins were provided by M. Takeichi (Institute of Physical and Chemi-
cal Research CDB, Hyogo, Japan). cDNA for mouse P-cadherin was 
obtained from the Institute of Physical and Chemical Research Bio  Resource 
Center (Ibaraki, Japan). cDNAs for R-, VE-, and M-cadherin were ampli-
fi  ed by RT-PCR from the brain of a C57BL/6J mouse and from C2C12 
cells, respectively. These cDNAs were independently subcloned into a 
pMXs vector or a pMXs-IRES-EGFP vector and used for retroviral trans-
duction. A BW5147 cell line expressing E-cadherin was established from 
BW5147 cells transduced with the pMXs vector with E-cadherin cDNA by 
limiting dilution.
Preparation of E-cadherin–Fc fusion protein. Preparation of the E-
cadherin–Fc fusion protein will be described elsewhere (unpublished data). 
In brief, cDNA fragments encoding the extracellular region of mouse 
E-cadherin and the Fc segment of human IgG1 fused with an IgA tail piece 
(a gift from H. Arase, Osaka University, Osaka, Japan) were cloned into 
a pRc/CMV1 vector (Invitrogen). 293T cells were transfected with a 5:1 
mixture of the E-cadherin–Fc expression vector and an expression vector for 
mouse furin (pCMVmFur; a gift from K. Nakayama, Kyoto University, 
Kyoto, Japan), and the culture supernatants containing 0.2 μg/ml of JEM VOL. 203, February 20, 2006  295
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E-  cadherin–Fc protein were used to stain cells for 30 min at 37°C, followed 
by staining with PE-goat anti–human IgG Fc antibody preabsorbed with 
hamster serum. Where indicated, cells were incubated with 10 μg/ml of 
hamster anti–mouse KLRG1 mAb (2F1) or control hamster antibody, before 
staining with E-cadherin–Fc fusion protein.
Cytotoxicity assays. The mouse NK cell line NK03, which was estab-
lished from spleen NK cells of C57BL/6J mice in our laboratory (unpub-
lished data), was transduced with mouse KLRG1 cDNA subcloned into 
the pMXs-IRES-EGFP vector. The cells with high levels of EGFP ex-
pression were sorted using a FACSVantage SE. The cytotoxicity of NK 
cells against various target cells was examined using a standard 4 h 51Cr-re-
lease assay, as described (30). Where indicated, 5 μg/ml of the indicated 
mAb was included in the assays. F9 cells and BW5147 cells lack expression 
of Fcγ receptors, excluding the possibility of reverse antibody-dependent 
cell cytotoxicity.
Online supplemental material. Table S1 lists the cell lines used to 
identify the KLRG1 ligands. Fig. S1 describes the sensitivity of the pu-
tative KLRG1 ligand(s) to trypsin-EDTA treatment. Fig. S2 describes 
RT-PCR analysis for expression of cadherins in mouse cell lines. Fig. S3 
describes   expression of cadherins on BW5147 cells transduced with vari-
ous cadherins. Online supplemental material is available at http://www.jem.
org/cgi/content/full/jem.20051986/DC1.
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